MPM Oncology Impact Management »

Abivax SA F shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Abivax SA F (ABVX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Abivax SA F

Tip: Access up to 7 years of quarterly data

All positions including Abivax SA F held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Abivax SA F by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $7.6M 56k 134.86

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Abivax SA F

TCG Crossover Management
UBS Group
Darwin Global Management
Point72 Asset Management
Vestal Point Capital
Susquehanna International
Caligan Partners
FMR
Paradigm Biocapital Advisors
Cormorant Asset Management
ADAR1 Capital Management
Barclays
Millennium Management
Westfield Capital Management Company
Adage Capital Partners GP

View all funds holding Abivax SA F